Clinical trials: Empagliflozin
Healthy Volunteers
Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers
- Trial name
- NCT06339788
- Testing
- HD-P023, Teneligliptin, Empagliflozin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Diabetes Mellitus, Type 2
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
- Trial name
- NCT04295005
- Testing
- Empagliflozin, DPP-4i, GLP-1-RA
- Where
- Germany
- Volunteers
- 24,500 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Diabetes Mellitus
Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions
Aim: To study the effectiveness and safety of empagliflozin as a preoperative preparation tool, as well as to improve the long-term prognosis of planned percutaneous coronary interventions in patients with type 2 diabetes
- Conditions
- Coronary Artery Disease, Diabetes Mellitus, Percutaneous Coronary Intervention
- Trial name
- SAFARY (NCT04497792)
- Testing
- Empagliflozin 10Mg Tab, hypoglycemic therapy
- Volunteers
- 40 people
- Sponsor
- Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors generally and empagliflozin specifically have shown cardiovascular benefits in patients with heart failure (HF), but the underlying mechanisms remain unclear.
- Conditions
- Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
- Trial name
- NCT05139472
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Texas Southwestern Medical Center
Atrial Fibrillation, Heart Failure
Empagliflozin and Atrial Fibrillation Treatment
The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, in patients with diabetes mellitus or overweight, heart failure and atrial fibrillation.
- Conditions
- Atrial Fibrillation, Heart Failure, Obesity, Diabetes Mellitus
- Trial name
- EMPA-AF (NCT04583813)
- Testing
- Empagliflozin
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Miulli General Hospital
Myocardial Suppression
Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging
The overall objective of this study is to assess if the empagliflozin has the potential to substitute the high fat low carb (HFLC) diet for the preparation of cardiovascular FDG-PET studies.
- Trial name
- SWEET-HEART (NCT06350903)
- Testing
- Fast + High-fat low-carbohydrate diet, Fast + Empagliflozin
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Matthieu Pelletier-Galarneau, MD MSc
Healthy Subjects
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6014 and each component in healthy adult volunteers in fast condition.
- Trial name
- NCT05823870
- Testing
- DW6014
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Heart Failure, Obesity
The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
The aim of this trial is to assess the effect of Empagliflozin on cardiac mass, volumes, cardiac biomarkers, metabolism, daily activity level, health-related quality of life in patients in elderly and obese patients with…
- Trial name
- NCT05084235
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Denmark
- Volunteers
- 191 people
- Sponsor
- Jacob Moller
Healthy
BI 10773 Administered as Oral Solution to Healthy Male Volunteers
Study to determine the pharmacokinetics of BI 10773 and total radioactivity including excretion mass balance, excretion pathways and metabolism following the oral administration of [14C] BI 10773
- Trial name
- NCT02172274
- Testing
- [14C]-BI 10773 - oral solution
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
SGLT2i, Pioglitazone, and Ketone Production in T2D
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
- Trial name
- NCT07053319
- Testing
- Empagliflozin 25 MG, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2, Coronary Artery Disease
POST-CABGDM: Empagliflozin in Perioperative CABG
Introduction: Diabetes Mellitus (DM) is a condition known to be associated with coronary artery disease (CAD) and its role as promoter of atherosclerosis is well stablished.
- Conditions
- Diabetes Mellitus, Type 2, Coronary Artery Disease, Coronary Artery Bypass Surgery, Acute Kidney Injury
- Trial name
- POST-CABGDM (NCT04523064)
- Testing
- Empagliflozin 25 MG
- Where
- Brazil
- Volunteers
- 155 people
- Sponsor
- University of Sao Paulo General Hospital
Type1diabetes
Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin
One of the challenges in the design of the artificial pancreas (AP) is preventing postprandial hyperglycemia. Beyond algorithmic solutions, one countermeasure to postprandial hyperglycemia that may enhance performance of the AP…
- Trial name
- CLASS15 (NCT03510000)
- Testing
- Empagliflozin 25mg, Single hormone artificial pancreas, Meal strategies
- Where
- 3 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Hypertension
Short Term Effect of Empagliflozin in Hypertension
The investigators assessed the 6-week effect of once daily 25mg SGLT2-i Empagliflozin on left ventricular diastolic function and blood pressure profile in non diabetic hypertensive patients
- Trial name
- EMPHYT (NCT04203914)
- Testing
- Empagliflozin Tablets
- Where
- 2 sites in Cameroon
- Volunteers
- 15 people
- Sponsor
- Yaounde Central Hospital
Diabetes Mellitus, Type 2
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
- Trial name
- NCT02589626
- Testing
- empagliflozin 10mg, empagliflozin 25 mg
- Where
- 16 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Hyperglycemia
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01719003
- Testing
- Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd
- Where
- 190 sites in United States, Brazil and 19 more
- Volunteers
- 1,413 people
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)
Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Empagliflozin \& Metformin HCL from Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T…
- Trial name
- NCT05132023
- Testing
- Empagliflozin & Metformin (Test), Empagliflozin & Metformin (Reference)
- Where
- Egypt
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Genuine Research Center, Egypt
Coronary Artery Disease
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)
Sodium-glucose contrasporter-2 (SGLT-2) inhibitors make up an antidiabetic medication that promotes glycosuria. They are known to have an indirect reduction in cardiovascular complications, based on a series of in-depth studies.
- Trial name
- EpiCAD (NCT06128096)
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Where
- Malaysia
- Volunteers
- 360 people
- Sponsor
- Clinical Research Centre, Malaysia
Heart Failure With Reduced Ejection Fraction
Initiation of ARNi and SGLT2i in Patients With HFrEF
Heart failure (HF) is a condition in which the heart does not contract ("pump") or relax well, leading to insufficient perfusion of vital organs.
- Trial name
- INITIATE (NCT05989503)
- Testing
- Sacubitril-valsartan, SGLT2 inhibitor
- Where
- 5 sites in Portugal
- Volunteers
- 62 people
- Sponsor
- Universidade do Porto
Diabetes Mellitus, Type 2
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.
- Trial name
- NCT02121483
- Testing
- empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 27 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, Mild Cognitive Impairment
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
This is an investigator-led prospective, randomized, open label, parallel study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function in T2DM patients with mild…
- Trial name
- LIGHT-MCI (NCT05313529)
- Testing
- Liraglutide, Empagliflozin, Linagliptin
- Where
- 5 sites in China
- Volunteers
- 396 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School